Pincer Biotech appoints CEO, cementing goal to combat antibiotic resistance

The firm wants to develop treatments targeting certain types of antibiotic-resistant bacteria, and has recently brought in the founder of Expres2ion as chief executive, intensifying the firm’s work.

Charlotte Dyring, newly appointed CEO of Pincer Biotech | Photo: Privat / Charlotte Dyring

What are the most pressing medical challenges when it comes to developing new drugs against antimicrobial resistance (AMR)?

The question was posed by a number of researchers, led by MD Lars Jørgen Østergaard, some years ago. With the aim of securing funds to develop new drugs, Østergaard contacted serial entrepreneur and investor Claus Hansen, ”who knows about the money side of things.”

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs